These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 10515299)

  • 1. Arylalkylamine drugs of abuse: an overview of drug discrimination studies.
    Glennon RA
    Pharmacol Biochem Behav; 1999 Oct; 64(2):251-6. PubMed ID: 10515299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stimulus properties of hallucinogenic phenalkylamines and related designer drugs: formulation of structure-activity relationships.
    Glennon RA
    NIDA Res Monogr; 1989; 94():43-67. PubMed ID: 2575229
    [No Abstract]   [Full Text] [Related]  

  • 3. Discriminative stimulus properties of hallucinogens and related designer drugs.
    Glennon RA
    NIDA Res Monogr; 1991; (116):25-44. PubMed ID: 1369672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Legal highs" - new players in the old drama.
    Zawilska JB
    Curr Drug Abuse Rev; 2011 Jun; 4(2):122-30. PubMed ID: 21711229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress report from the testing program for stimulant and depressant drugs (1996).
    France CP; Gerak LR; Rowlett JK; Woolverton WL; Winger G; Woods JH
    NIDA Res Monogr; 1998 Mar; 178():429-39. PubMed ID: 9686406
    [No Abstract]   [Full Text] [Related]  

  • 6. Progress report from the testing program for stimulant and depressant drug (1992).
    Woolverton WL; Nader MA; Winger G; Woods JH; Patrick GA; Harris LS
    NIDA Res Monogr; 1993; 132():579-94. PubMed ID: 8101976
    [No Abstract]   [Full Text] [Related]  

  • 7. Drug discrimination: A versatile tool for characterization of CNS safety pharmacology and potential for drug abuse.
    Swedberg MD
    J Pharmacol Toxicol Methods; 2016; 81():295-305. PubMed ID: 27235786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenylalkylamine stimulants, hallucinogens, and designer drugs.
    Glennon RA
    NIDA Res Monogr; 1990; 105():154-60. PubMed ID: 1678860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The development from drug to designer drug].
    Askaa B; Horwitz H; Wøien VA; Høgberg LC; Jürgens G
    Ugeskr Laeger; 2014 Oct; 176(42):. PubMed ID: 25316367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthetic cathinones: "a khat and mouse game".
    Katz DP; Bhattacharya D; Bhattacharya S; Deruiter J; Clark CR; Suppiramaniam V; Dhanasekaran M
    Toxicol Lett; 2014 Sep; 229(2):349-56. PubMed ID: 24973490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling.
    Liechti M
    Swiss Med Wkly; 2015; 145():w14043. PubMed ID: 25588018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Ecstasy: from recreational drug to toxic substance].
    Franck N; Bertrand J
    Rev Med Liege; 1997 Nov; 52(11):715-22. PubMed ID: 9480498
    [No Abstract]   [Full Text] [Related]  

  • 13. Stimulus effects of three sulfur-containing psychoactive agents.
    Khorana N; Pullagurla MR; Dukat M; Young R; Glennon RA
    Pharmacol Biochem Behav; 2004 Aug; 78(4):821-6. PubMed ID: 15301941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical toxicology of newer recreational drugs.
    Hill SL; Thomas SH
    Clin Toxicol (Phila); 2011 Oct; 49(8):705-19. PubMed ID: 21970769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hallucinogens in Drug Discrimination.
    Baker LE
    Curr Top Behav Neurosci; 2018; 36():201-219. PubMed ID: 28484970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Mephedrone: a designer drug of recent use in France].
    Debruyne D; Courné MA; Le Boisselier R; Djezzar S; Gérardin M; Boucher A; Karila L; Coquerel A; Mallaret M
    Therapie; 2010; 65(6):519-24. PubMed ID: 21176758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress report from the Testing Program for Stimulant and Depressant Drugs (1991).
    Winger G; Woods JH; Patrick GA; Powell LJ; Harris LS; Nader MA; Woolverton WL
    NIDA Res Monogr; 1992; 119():625-39. PubMed ID: 1359421
    [No Abstract]   [Full Text] [Related]  

  • 18. A Role for Sigma Receptors in Stimulant Self-Administration and Addiction.
    Katz JL; Hiranita T; Hong WC; Job MO; McCurdy CR
    Handb Exp Pharmacol; 2017; 244():177-218. PubMed ID: 28110353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 2014 Philip S. Portoghese Medicinal Chemistry Lectureship: The "Phenylalkylaminome" with a Focus on Selected Drugs of Abuse.
    Glennon RA
    J Med Chem; 2017 Apr; 60(7):2605-2628. PubMed ID: 28244748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel psychoactive substances: the pharmacology of stimulants and hallucinogens.
    Schifano F; Papanti GD; Orsolini L; Corkery JM
    Expert Rev Clin Pharmacol; 2016 Jul; 9(7):943-54. PubMed ID: 26985969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.